Electrocardiographic left ventricular hypertrophy predicts arrhythmia and mortality in patients with ischemic cardiomyopathy

Journal of Interventional Cardiac Electrophysiology

Volumn 34, Issue 3, 2012, Pages 237-245

  Bender, Seth R ^a   Friedman, Daniel J ^a   Markowitz, Steven M ^a   Lerman, Bruce B ^a   Okin, Peter M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Arrhythmia; Cardiomyopathy; Electrocardiography; Hypertrophy

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SPIRONOLACTONE;

ARTICLE; BLOOD PRESSURE; DEATH; DEFIBRILLATOR; DRUG USE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; MALE; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 84864723181     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-011-9661-2     Document Type: Article

References (42)

1. Moss, A. J. (1983). Risk stratification and survival after myocardial infarction. New England Journal of Medicine, 309(6), 331-336.
2. Rouleau, J. L., Talajic, M., Sussex, B., Potvin, L., Warnica, W., Davies, R. F., et al. (1996). Myocardial infarction patients in the 1990s-Their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. Journal of the American College of Cardiology, 27(5), 1119-1127. (Pubitemid 26117701)
3. Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. The New England Journal of Medicine, 352(3), 225-237. (Pubitemid 40110811)
4. Buxton,A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (1999). A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. The New England Journal of Medicine, 341(25), 1882-1890.
5. Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., et al. (1996). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. The New England Journal of Medicine, 335(26), 1933-1940. (Pubitemid 26428217)
6. Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England Journal of Medicine, 346 (12), 877-883. (Pubitemid 34984635)
7. Moss, A. J., Greenberg, H., Case, R. B., Zareba, W., Hall, W. J., Brown, M. W., et al. (2004). Long-Term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation, 110(25), 3760-3765. (Pubitemid 40023973)
8. Rosenqvist, M., Beyer, T., Block, M., den Dulk, K., Minten, J., & Lindemans, F. (1998). Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation, 98(7), 663-670. (Pubitemid 28387493)
9. Sweeney, M. O., Wathen, M. S., Volosin, K., Abdalla, I., DeGroot, P. J., Otterness, M. F., et al. (2005). Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation, 111(22), 2898-2905. (Pubitemid 40814182)
10. Mushlin, A. I., Hall, W. J., Zwanziger, J., Gajary, E., Andrews, M., Marron, R., et al. (1998). The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation, 97(21), 2129-2135. (Pubitemid 28262120)
11. Zwanziger, J., Hall, W. J., Dick, A. W., Zhao, H., Mushlin, A. I., Hahn, R. M., et al. (2006). The cost effectiveness of implantable cardioverter- defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. Journal of the American College of Cardiology, 47(11), 2310-2318. (Pubitemid 43795065)
12. Gomes, J. A., Cain, M. E., Buxton, A. E., Josephson, M. E., Lee, K. L., & Hafley, G. E. (2001). Prediction of long-Term outcomes by signal-Averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation, 104(4), 436-441. (Pubitemid 32678274)
13. Bloomfield, D. M., Steinman, R. C., Namerow, P. B., Parides, M., Davidenko, J., Kaufman, E. S., et al. (2004). Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation, 110(14), 1885-1889. (Pubitemid 39331896)
14. Chow, T., Kereiakes, D. J., Bartone, C., Booth, T., Schloss, E. J., Waller, T., et al. (2007). Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. Journal of the American College of Cardiology, 49(1), 50-58. (Pubitemid 46026898)
15. Hohnloser, S. H., Ikeda, T., Bloomfield, D. M., Dabbous, O. H., & Cohen, R. J. (2003). T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet, 362(9378), 125-126. (Pubitemid 36831024)
16. Borleffs, C. J., Scherptong, R. W., Man, S. C., van Welsenes, G. H., Bax, J. J., van Erven, L., et al. (2009). Predicting ventricular arrhythmias in patients with ischemic heart disease: clinical application of the ECG-derived QRS-T angle. Circulation. Arrhythmia and Electrophysiology, 2(5), 548-554.
17. Buxton, A. E., Sweeney, M. O., Wathen, M. S., Josephson, M. E., Otterness, M. F., Hogan-Miller, E., et al. (2005). QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. Journal of the American College of Cardiology, 46(2), 310-316. (Pubitemid 40966861)
18. Dhar, R., Alsheikh-Ali, A. A., Estes, N. A., 3rd, Moss, A. J., Zareba, W., Daubert, J. P., et al. (2008). Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm, 5(6), 807-813.
19. Kalahasti, V., Nambi, V., Martin, D. O., Lam, C. T., Yamada, D., Wilkoff, B. L., et al. (2003). QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. The American Journal of Cardiology, 92(7), 798-803. (Pubitemid 37163573)
20. Singh, J. P., Hall, W. J., McNitt, S., Wang, H., Daubert, J. P., Zareba, W., et al. (2005). Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Journal of the American College of Cardiology, 46(9), 1712-1720. (Pubitemid 41531628)
21. Mathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q., et al. (2001). Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation, 104 (14), 1615-1621. (Pubitemid 32947523)
22. Okin, P. M., Devereux, R. B., Jern, S., Kjeldsen, S. E., Julius, S., Nieminen, M. S., et al. (2004). Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. Journal of the American Medical Association, 292(19), 2343-2349. (Pubitemid 39491918)
23. Verdecchia, P., Schillaci, G., Borgioni, C., Ciucci, A., Gattobigio, R., Zampi, I., et al. (1998). Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. Journal of the American College of Cardiology, 31(2), 383-390. (Pubitemid 28153459)
24. Wachtell, K., Okin, P. M., Olsen, M. H., Dahlof, B., Devereux, R. B., Ibsen, H., et al. (2007). Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation, 116(7), 700-705. (Pubitemid 47260463)
25. Zimetbaum, P. J., Buxton, A. E., Batsford, W., Fisher, J. D., Hafley, G. E., Lee, K. L., et al. (2004). Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation, 110(7), 766-769. (Pubitemid 39096001)
26. Cantillon, D. J., Stein, K. M., Markowitz, S. M., Mittal, S., Shah, B. K., Morin, D. P., et al. (2007). Predictive value of microvolt Twave alternans in patients with left ventricular dysfunction. Journal of the American College of Cardiology, 50(2), 166-173. (Pubitemid 47002188)
27. Okin, P. M., Devereux, R. B., Kors, J. A., van Herpen, G., Crow, R. S., Fabsitz, R. R., et al. (2001). Computerized ST depression analysis improves prediction of all-cause and cardiovascular mortality: the strong heart study. Annals of Noninvasive Electrocardiology, 6(2), 107-116. (Pubitemid 32423396)
28. Kannel, W. B. (1983). Prevalence and natural history of electrocardiographic left ventricular hypertrophy. American Journal of Medicine, 75(3A), 4-11. (Pubitemid 13009927)
29. Kannel, W. B., Gordon, T., Castelli, W. P., & Margolis, J. R. (1970). Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Annals of Internal Medicine, 72(6), 813-822.
30. Kannel, W. B., Gordon, T., & Offutt, D. (1969). Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Annals of Internal Medicine, 71(1), 89-105.
31. Kannel, W. B., & Schatzkin, A. (1985). Sudden death: lessons from subsets in population studies. Journal of the American College of Cardiology, 5(6 Suppl), 141B-149B. (Pubitemid 15063755)
32. Sundstrom, J., Lind, L., Arnlov, J., Zethelius, B., Andren, B., & Lithell, H. O. (2001). Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation, 103 (19), 2346-2351. (Pubitemid 32448798)
33. Ishikawa, J., Ishikawa, S., Kabutoya, T., Gotoh, T., Kayaba, K., Schwartz, J. E., et al. (2009). Cornell product left ventricular hypertrophy in electrocardiogram and the risk of stroke in a general population. Hypertension, 53(1), 28-34.
34. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1989). Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Annals of Internal Medicine, 110(2), 101-107. (Pubitemid 19033194)
35. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. The New England Journal of Medicine, 322(22), 1561-1566. (Pubitemid 20176696)
36. Casale, P. N., Devereux, R. B., Milner, M., Zullo, G., Harshfield, G. A., Pickering, T. G., et al. (1986). Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Annals of Internal Medicine, 105(2), 173-178. (Pubitemid 16039288)
37. Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Annals of Internal Medicine, 114(5), 345-352.
38. Levy, D., Salomon, M., D'Agostino, R. B., Belanger, A. J., & Kannel, W. B. (1994). Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90(4), 1786-1793. (Pubitemid 24320926)
39. Reinier, K., Dervan, C., Singh, T., Uy-Evanado, A., Lai, S., Gunson, K., et al. (2011). Increased left ventricular mass and decreased left ventricular systolic function have independent pathways to ventricular arrhythmogenesis in coronary artery disease. Heart Rhythm, 8, 1177-1182.
40. Hancock, E. W., Deal, B. J., Mirvis, D. M., Okin, P., Kligfield, P., Gettes, L. S., et al. (2009). AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. Journal of the American College of Cardiology, 53(11), 992-1002.
41. Molloy, T. J., Okin, P. M., Devereux, R. B., & Kligfield, P. (1992). Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. Journal of the American College of Cardiology, 20(5), 1180-1186.
42. Miner, E. C., & Miller, W. L. (2006). A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clinic Proceedings, 81(1), 71-76. (Pubitemid 43054320)